Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae | Zendy

Jessica B. Cprek | Zendy; Jason C Gallagher | Zendy

Open Access

Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae

Author(s) -

Jessica B. Cprek,

Jason C Gallagher

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01569-15

Subject(s) - ertapenem , klebsiella pneumoniae , carbapenem , medicine , pneumonia , klebsiella pneumonia , klebsiella , urinary system , klebsiella infections , microbiology and biotechnology , antibiotics , meropenem , pseudomonas aeruginosa , antibiotic resistance , biology , bacteria , escherichia coli , biochemistry , genetics , gene

We describe outcomes of patients with infections with carbapenem-resistantKlebsiella pneumoniae (CRKP) who received ertapenem-containing double-carbapenem therapy (ECDCT). Clinical success was observed in 7/18 (39%) patients overall: bloodstream infections, 3/7 (43%); pneumonia, 1/5 (20%); intraabdominal infections, 0/2 (0%); urinary tract infections, 2/3 (67%); and a skin and skin structure infection, 1/1 (100%). Microbiologic success was observed in 11/14 (79%) evaluable patients; 5/18 (28%) patients died. ECDCT may be effective for CRKP infections with limited treatment options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research